Suppr超能文献

KDM2b/JHDM1b,一种 H3K36me2 特异性去甲基化酶,是急性髓系白血病起始和维持所必需的。

KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.

机构信息

Howard Hughes Medical Institute, and Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA.

出版信息

Blood. 2011 Apr 7;117(14):3869-80. doi: 10.1182/blood-2010-10-312736. Epub 2011 Feb 10.

Abstract

The histone H3 lysine 36 dimethyl-specific demethylase KDM2b/JHDM1b, which is highly expressed in various human leukemias, was previously found to be important in regulating cell proliferation and cellular senescence. However, its functions in leukemia development and maintenance are unclear. Here, we demonstrate that ectopic expression of Kdm2b/Jhdm1b is sufficient to transform hematopoietic progenitors. Conversely, depletion of Kdm2b/Jhdm1b in hematopoietic progenitors significantly impairs Hoxa9/Meis1-induced leukemic transformation. In leukemic stem cells, knockdown of Kdm2b/Jhdm1b impairs their self-renewing capability in vitro and in vivo. The functions of Kdm2b/Jhdm1b are mediated by its silencing of p15(Ink4b) expression through active demethylation of histone H3 lysine 36 dimethyl. Thus, our study suggests that Kdm2b/Jhdm1b functions as an oncogene and plays a critical role in leukemia development and maintenance.

摘要

组蛋白 H3 赖氨酸 36 二甲基特异性去甲基酶 KDM2b/JHDM1b 在各种人类白血病中高度表达,先前被发现对调节细胞增殖和细胞衰老很重要。然而,其在白血病发生和维持中的作用尚不清楚。在这里,我们证明了 Kdm2b/Jhdm1b 的异位表达足以转化造血祖细胞。相反,在造血祖细胞中耗尽 Kdm2b/Jhdm1b 会显著损害 Hoxa9/Meis1 诱导的白血病转化。在白血病干细胞中,Kdm2b/Jhdm1b 的敲低会损害其体外和体内的自我更新能力。Kdm2b/Jhdm1b 的功能是通过其对组蛋白 H3 赖氨酸 36 二甲基的活性去甲基化来沉默 p15(Ink4b)的表达来介导的。因此,我们的研究表明,Kdm2b/Jhdm1b 是一种癌基因,在白血病的发生和维持中起着关键作用。

相似文献

1
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
Blood. 2011 Apr 7;117(14):3869-80. doi: 10.1182/blood-2010-10-312736. Epub 2011 Feb 10.
2
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
Nat Struct Mol Biol. 2008 Nov;15(11):1169-75. doi: 10.1038/nsmb.1499. Epub 2008 Oct 5.
4
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
J Clin Invest. 2016 Mar 1;126(3):905-20. doi: 10.1172/JCI84014. Epub 2016 Jan 25.
7
KDM2B is a histone H3K79 demethylase and induces transcriptional repression via sirtuin-1-mediated chromatin silencing.
FASEB J. 2018 Oct;32(10):5737-5750. doi: 10.1096/fj.201800242R. Epub 2018 May 15.
8
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Blood. 2015 May 28;125(22):3437-46. doi: 10.1182/blood-2014-03-562694. Epub 2015 Apr 14.

引用本文的文献

1
Molecular Mechanisms of KSHV Latency Establishment and Maintenance.
Curr Clin Microbiol Rep. 2024 Dec;11(4):220-230. doi: 10.1007/s40588-024-00232-x. Epub 2024 Jul 19.
2
Epigenetic regulation of cancer stemness.
Signal Transduct Target Ther. 2025 Aug 1;10(1):243. doi: 10.1038/s41392-025-02340-6.
3
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Signal Transduct Target Ther. 2025 Jul 18;10(1):219. doi: 10.1038/s41392-025-02266-z.
4
Current advances and future directions in targeting histone demethylases for cancer therapy.
Mol Cells. 2025 Mar;48(3):100192. doi: 10.1016/j.mocell.2025.100192. Epub 2025 Feb 10.
5
Marek's disease virus-encoded microRNA-M6-5p facilitates viral latent infection by targeting histone demethylase KDM2B.
J Virol. 2025 Feb 25;99(2):e0200724. doi: 10.1128/jvi.02007-24. Epub 2025 Jan 22.
6
Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy.
Front Mol Med. 2024 Sep 6;4:1426454. doi: 10.3389/fmmed.2024.1426454. eCollection 2024.
8
Targeting epigenetic alterations in cancer stem cells.
Front Mol Med. 2022 Sep 20;2:1011882. doi: 10.3389/fmmed.2022.1011882. eCollection 2022.
9
KDM2B is required for ribosome biogenesis and its depletion unequally affects mRNA translation.
bioRxiv. 2024 Jun 6:2024.05.22.595403. doi: 10.1101/2024.05.22.595403.
10
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells.
Sci Adv. 2024 Apr 19;10(16):eadi1782. doi: 10.1126/sciadv.adi1782. Epub 2024 Apr 17.

本文引用的文献

1
Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML.
Blood. 2010 Apr 15;115(15):3098-108. doi: 10.1182/blood-2009-07-233858. Epub 2010 Feb 26.
2
Heterogeneity in cancer: cancer stem cells versus clonal evolution.
Cell. 2009 Sep 4;138(5):822-9. doi: 10.1016/j.cell.2009.08.017.
4
The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Cold Spring Harb Symp Quant Biol. 2008;73:461-7. doi: 10.1101/sqb.2008.73.039. Epub 2008 Nov 21.
5
Establishment of a normal hematopoietic and leukemia stem cell hierarchy.
Cold Spring Harb Symp Quant Biol. 2008;73:439-49. doi: 10.1101/sqb.2008.73.031. Epub 2008 Nov 6.
7
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
Nat Struct Mol Biol. 2008 Nov;15(11):1169-75. doi: 10.1038/nsmb.1499. Epub 2008 Oct 5.
8
Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process.
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1907-12. doi: 10.1073/pnas.0711865105. Epub 2008 Feb 4.
9
Role of hPHF1 in H3K27 methylation and Hox gene silencing.
Mol Cell Biol. 2008 Mar;28(5):1862-72. doi: 10.1128/MCB.01589-07. Epub 2007 Dec 17.
10
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a.
Nature. 2007 Aug 23;448(7156):943-6. doi: 10.1038/nature06084.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验